The CSL Board is responsible for oversight of the management of the Company and providing strategic direction. The Executive Management Group is responsible for the day to day running of CSL.

CSL Board Members

	Elizabeth A Alexander, AM. BCom, FCPA, FCA, FAICD Finance and Risk Management (resident in Victoria). Chairman Miss Alexander was appointed to the CSL Board in July 1991 and became Chairman on 1 October 2006. She is a Director of the Dexus Property Group and of Medibank Private Limited. Miss Alexander is a former National President of the Australian Society of Certified Practising Accountants and of the Australian Institute of Company Directors. She is Chairman of the Board of Advice to the Salvation Army (Southern Command), National President of the Winston Churchill Fellowship Trust and Chairman of the Finance Committee of Melbourne University. Miss Alexander is a Member of the Audit and Risk Management Committee.
	Brian A McNamee, AO, MB, BS, FAICD Pharmaceutical Industry, Medicine (resident in Victoria). Chief Executive Officer and Managing Director Dr McNamee was appointed to the CSL Board in 1990 and is the Chief Executive Officer and Managing Director. He is a former Director of the Peter MacCallum Cancer Foundation Ltd. Dr McNamee completed Bachelor of Medicine and Bachelor of Surgery Degrees at the University of Melbourne in 1979. Dr McNamee is a Fellow of the Australian Academy of Technical Services and Engineering (FTSE).
	Antoni M Cipa, B.Bus (Acc), Grad.Dip (Acc), CPA, ACIS Finance (resident in Victoria). Finance Director Mr Cipa was appointed to the CSL Board as Finance Director in August 2000. Mr Cipa commenced his employment at CSL in 1990 as Finance Manager. He was instrumental in the float of the Company in 1994 at which time he was appointed Chief Financial Officer.
	Peter Turner, BSc, MBA Pharmaceutical Industry (resident in Pennsylvania, USA) Chief Operating Officer, CSL Group and President, CSL Behring Mr Turner was appointed to the CSL Board in December 2009. Mr Turner has more than 40 years experience in the biopharmaceutical industry. His expertise includes plasma fractionation, research and development, production, engineering and management. Mr Turner contributed to the successful acquisition of Aventis Behring to form CSL Behring in 2004 and has served as President of CSL Behring since that time.
	John Akehurst, MA (Oxon), FIMechE Engineering, Management (resident in Western Australia). Mr Akehurst was appointed to the CSL Board in April 2004. He had 30 years’ executive experience in the international hydrocarbon industry, including 7 years as Managing Director and CEO of Woodside Petroleum Ltd. Mr Akehurst is a member of the Board of the Reserve Bank of Australia. He is a Director of Origin Energy Limited and of Securency International Pty Ltd. He was formerly Chairman of Alinta Limited and of Coogee Resources Limited and is a former Director of Oil Search Limited. He is Chairman of The National Centre for Asbestos Related Diseases and The Fortitude Foundation and a Director of the University of Western Australia’s Business School and of Curtin University’s Sustainable Development Institute. Mr Akehurst is a Member of the Human Resources Committee.
	David Anstice, BEc International Pharmaceutical Industry (resident in Pennsylvania, USA) Mr Anstice was appointed to the CSL Board in September 2008. Mr Anstice was a long-time member of the Board of Directors and Executive Committee of the US Biotechnology Industry Organisation, and has 40 years’ experience in the global pharmaceutical industry. Until recently Mr Anstice was for many years a senior executive of Merck & Co Inc, serving at various times as President of Merck Human Health for US/Canada/Latin America, Europe, Japan and Asia, and as Executive VP. Mr. Anstice is a Director of Alkermes, Inc., in Cambridge, Massachusetts, a Director of the United States Studies Centre at the University of Sydney, and Chairman of the USA Foundation of the University of Sydney. He is an Adjunct Professor in the Faculty of Economics and Business at Sydney University and holds a Bachelor of Economics from that University which he obtained in 1970. Mr Anstice is a member of the Human Resources Committee and the Innovation and Development Committee.
	Ian A Renard, BA, LLM, LLD(Hon), FAICD Law (resident in Victoria). Mr Renard was appointed to the CSL Board in August 1998. For many years he practised in company and commercial law. He was a Director of Newcrest Mining Limited from 1998 until September 2006, and is a Director of Hillview Quarries Pty Ltd, SP Australia Networks (Distribution) Ltd and SP Australia Networks (Transmission) Ltd. Mr Renard was the Chancellor of the University of Melbourne until 10 January 2009. Mr Renard is Chairman of the Audit and Risk Management Committee.
	Maurice A Renshaw, B.Pharm. International Pharmaceutical Industry (resident in NSW). Mr Renshaw was appointed to the CSL Board in July 2004. Formerly, he was Vice-President of Pfizer Inc, USA, Executive Vice-President, Pfizer Global Consumer Group and President of Pfizer’s Global Consumer Healthcare Division. Prior to his positions in Pfizer, Mr Renshaw was Vice-President of Warner Lambert Co. and President of Parke-Davis USA. Mr Renshaw has had more than 30 years’ experience in the international pharmaceutical industry. Mr Renshaw is Chairman of the Innovation and Development Committee.
	John Shine, AO, BSc (Hons), PhD, DSc, FAA Pharmaceutical Industry, Medicine (resident in NSW). Professor Shine was appointed to the CSL Board in June 2006. He is Executive Director of the Garvan Institute of Medical Research and a Board Member of the Garvan Research Foundation. He is Professor of Molecular Biology and Professor of Medicine at the University of NSW, and a Director of many scientific research and medical bodies throughout Australia. Professor Shine was formerly Chairman of the National Health and Medical Research Council (NHMRC) and a Member of the Prime Minister’s Science, Engineering and Innovation Council (PMSEIC). Professor Shine is a member of the Innovation and Development Committee.
	David J Simpson, FCPA Finance and Management (resident in Victoria). Mr Simpson was appointed to the CSL Board in September 2006. He is the non-executive Chairman of Aristocrat Leisure Limited. For many years, Mr Simpson was Finance Director of Tabcorp Holdings Limited and before that Executive General Manager Finance of Southcorp Holdings Ltd. Mr Simpson is Chairman of the Human Resources Committee and a member of the Audit and Risk Management Committee.
	Edward H Bailey, LLB, B.Com, FCSA Company Secretary

Privacy | Terms of Use | Employees | Webmaster